Psoriasis is a chronic dermatitis with unknown chronic systemic inflammatory diseases (CSID) that have same immunopathogenesis. Psoriasis is also an erythematous, scaly chronic inflammatory dermatitis with a complex immunologic basis. Psoriatic patients also suffer from comorbidities such as cancer, obesity, hypertension, insulin resistance, coronary artery diseases, metabolic syndrome, and other immune-related conditions that have similar pathogenic features. Cytokines released from these diseases cause similar clinical symptoms. It is well known that the eNOS gene polymorphism may cause endothelial dysfunction, which is a common finding between CSID group (e.g., hypertension, atherosclerosis, chronic inflammation, type 2 diabetes, etc.). Many different studies have been performed for investigating the correlation of cardiovascular diseases with psoriasis, and cardiovascular morbidity and mortality.
were observed to be increased in psoriatic patients.\textsuperscript{1-10}

Inflammatory processes play an important role in etiology and pathogenesis of both cardiovascular diseases and psoriasis.\textsuperscript{3} Nitric oxide is a vasoactive substance produced from L-arginine in the vascular endothelium by endothelial nitric oxide synthase (\textit{eNOS}) enzyme, and it is the main mediator of endothelial-dependent vasodilatation by the effect of vascular smooth muscle relaxation.\textsuperscript{11} It plays a major role in regional blood flow regulation and inhibits thrombocyte aggregation.\textsuperscript{12} \textit{eNOS} gene mutations have been shown to be risk factors for coronary artery disease, myocardial infarction, and hypertension.\textsuperscript{13-16}

Recent reports have shown that cardiovascular disease rates increase among psoriatic patients treated with systemic anti-inflammatory drugs. Therefore, determining psoriatic patients with a higher risk of hypertension is crucial to optimize required doses of systemic medications. Early diagnosis and treatment of hypertension risk in psoriatic patients will be beneficial in mortality prevention. \textit{eNOS} Glu298Asp polymorphism may be used as a marker gene to determine the hypertension risk in psoriatic patients, thus enabling dermatologists to identify patients with hypertension risk and manage the medication plan carefully.

The current study aimed to find out the possible association between \textit{eNOS} polymorphism and hypertension in psoriasis. The results of our study are important for assessing interactions between \textit{eNOS} gene and hypertension treatment among psoriatic patients.

**PATIENTS AND METHODS**

**Design and Setting**

A case-control study was performed to define genotype and allelic profiles of polymorphic \textit{eNOS} Glu298Asp gene in hypertensive psoriatic patients in the University Hospital, Canakkale, Turkey.

**Patients, Clinical Diagnosis, and Laboratory Assessment**

A total of 75 psoriatic patients (21 hypertensive \textsuperscript{[28%]}, 54 non-hypertensive \textsuperscript{[72%]}, 30 male \textsuperscript{[40%]}, 45 female \textsuperscript{[60%]}, and the mean age-max: 44.7 \textsuperscript{[14.1] \textsuperscript{[18-80]}}) and 55 normotensive subjects without a prior history of psoriasis in them and their families \textsuperscript{[23 male \textsuperscript{[41.8%]}, 32 female \textsuperscript{[58.2%]}]} and the mean age-max: 47.6 \textsuperscript{[9.9] \textsuperscript{[35-65]}}) were enrolled in the current study. Peripheral blood-EDTA samples were obtained during routine diagnosis from patients in Canakkale Onsekiz Mart University Training and Research Hospital by the collaboration of the Department of Medical Genetics between March 2010 and November 2012. All of the individuals in patient and control groups were informed, and written informed consent was obtained from them after the full explanation of the study.

**Genotyping**

Total genomic DNA was extracted from blood-EDTA samples by MagnaPure Compact (Roche, Germany) and Invitek kit extraction techniques (Invitek\textsuperscript{\textregistered}; Invisorb spin blood, Berlin, Germany). Target \textit{eNOS} gene was genotyped for patients and control groups by real-time PCR melting-curve analysis system (LightCycler 2.0, Roche, Germany). Gene amplification was performed using specific primers and probes belonging to polymorphic regions of target \textit{eNOS} Glu298Asp single-nucleotide polymorphism (SNP) (Rs1799983). For a total volume of 20 µl polymerase chain reaction (PCR), 5 µl genomic DNA, 7.4 µl PCR-grade fluid, 1.6 µl Mg2+ solution, 4 µl of primer and probe mixture, and 2 µl Roche Fast Start Master Mix real-time PCR, Germany, were used as a reaction mixture for amplification. Briefly, the amplification conditions included pre-denaturation at 95°C for 10 minutes; 45 cycles at 95°C for 5 seconds, at 60°C for 10 seconds, and at 72°C for 15 seconds; dissolution-melting at 95°C for 20 seconds, at 40°C for 20 seconds and 0.2 continuous mode at 85°C; and cooling at 40°C for 30 seconds. Non-mutated 298G/G allele (wild) was evaluated in the 640 channel at a melting temperature (Tm) of 52°C, whereas mutated 298A/A allele was evaluated again in the same channel at a Tm of 59°C.

**RESULTS**

Results showed variations in the \textit{eNOS} Glu298Asp polymorphism. A total of 75 psoriatic patients (mean age 44.7 (14.1) (18-80)) and 55 healthy controls (mean age 47.6 (9.9) (35-65)) were enrolled. In psoriatic patients, the mean diastolic blood pressure was 82.4 (9.9) mm Hg and systolic blood pressure was 128.2 (12) mm Hg. Twenty-one psoriatic patients (28\%) were identified as hypertensive psoriatic patients and received hypertension treatment.

In this study, the association of \textit{eNOS} polymorphism with psoriasis was analyzed by comparing psoriatic patients with normotensive non-psoriatic volunteers (Figure 1). (Table 1). The results revealed that the allele positivity of \textit{eNOS} gene increased the psoriasis risk 2.37 times more in psoriatic patients than in normotensive and non-psoriatic volunteers. (95\% confidence interval [CI] 1.14-4.96, \textit{P}=.02). The odds ratio for the risk of psoriasis due to the substitution of G to T in the \textit{eNOS} gene increased 2.13 times in hypertensive psoriatic patients (CI\% 1.14-3.99, \textit{P}=.017) than in
normotensive and non-psoriatic volunteers (Figure 1). These results suggest that eNOS polymorphism has a statistically significant effect to increase psoriasis risk.

The correlation of eNOS Glu298Asp mutation with hypertension in psoriatic patients was investigated by comparing them with normotensive, non-psoriatic volunteers (Table 2), aside psoriatic patients without hypertension (n:54; Table 3).

Hypertension accompanying psoriasis was detected in 7 out of 38 cases with normal (GG) genotypes, 13 out of 32 heterozygote (GT) genotypes, and 1 out of 5 mutant genotypes (TT) in the evaluation of 75 subjects with psoriasis.

When hypertensive psoriatic patients were compared with healthy (normotensive, non-psoriatic) individuals, an increased frequency of the eNOS rs1799983 T allele was found in hypertensive psoriatic patients (Odds ratio [OR]:3.04 95% CI 1.34-6.87, P=.0076). The results revealed that the allele positivity of eNOS gene increased the hypertension risk 4.88 times more among psoriatic patients than among normotensive, non-psoriatic volunteers (95% CI 1.66-14.32, P=.0027). When hypertensive psoriatic cases with heterozygote genotype (GT) were compared with the ones with normal genotype (GG), the conversion of single G allele into T allele increased the hypertension risk by 4.83 folds (OR 4.83, 95% CI 1.62-14.43, P=.0033). The overall increased risk of hypertension among psoriatic patients in the eNOS gene was 3.28 times (P=.003) more than among normotensive, non-psoriatic volunteers. It was determined in the study that T allele frequency belonging to the polymorphic eNOS Glu298Asp gene region was higher in hypertensive psoriatic cases than in normotensive, non-psoriatic individuals. These results also suggested that eNOS gene polymorphism rs1799983 G transversion to T was associated with an increased hypertension risk among psoriatic patients (Table 2).

The association of eNOS Glu298Asp (Rs1799983) polymorphism with hypertension was also performed by comparing hypertensive psoriatic patients with normotensive psoriatic cases. When cases with heterozygote genotype (GT) were compared with the ones with normal genotype (GG), the conversion of single G allele into T allele increased the hypertension risk by 3.03 folds (OR 3.03, 95% CI 1.03-8.94, P=.04). The poly-

---

**Table 1.** Genotype prevalence and T allele frequency of eNOS Glu298Asp SNP in the current psoriatic patients and healthy (normotensive and non-psoriatic) volunteers from the same population.

| Gene/ Genotypes | Patients (n:75) | Controls (n:55) | Groups | Allel Positivity [GG]vs[GT]+[TT] | P value | OR | CI (95%) |
|-----------------|----------------|----------------|--------|---------------------------------|---------|----|---------|
| eNOS Glu298Asp  |                |                |        |                                 |         |    |         |
| G/G             | 38/50.7        | 39/70.9        |        |                                 | .020    | 2.3| 1.14-4.96 |
| G/T             | 32/42.7        | 15/27.2        |        |                                 | .017    | 2.1| 1.14-3.99 |
| T/T             | 5/6.6          | 1/1.81         |        |                                 |         |    |         |

| Alleles         |                |                |        |                                 |         |    |         |
|-----------------|----------------|----------------|--------|---------------------------------|---------|----|---------|
| G/G             | 108/72.0       | 93/84.5        |        |                                 | .017    | 2.1| 1.14-3.99 |
| T/G             | 42/28.0        | 27/15.4        |        |                                 |         |    |         |

*Significant; OR: odds ratio; SNP: single-nucleotide polymorphism.
morphic $eNOS$ Glu298Asp gene region was higher in hypertensive psoriatic cases than in non-hypertensive psoriatic cases like healthy controls (Table 3).

**DISCUSSION**

As molecular basis and genetic susceptibility of diseases have been understood in the recent years, it was shown that basal vasodilatation deficiency, hypertension, and endothelial dysfunction developed in mice with the defect in the $eNOS$ gene region. The regain of vascular reactivity after $eNOS$ gene transplantation in $eNOS$-defective mice and rabbits with pulmonary hypertension and in vivo $eNOS$ injection studies in normal mice indicated the significance of $eNOS$ gene in preservation of healthy blood pressure levels.

Table 2. The comparison of genotype prevalence and allele frequency of target $eNOS$ Glu298Asp SNP for the hypertensive psoriatic sub-group patients and normotensive non-psoriatic healthy volunteers in the presented results.

| $eNOS$ Glu298Asp Polymorphism | Hypertensive Psoriatic Patients (n:21) | Normotensive Non-Psoriatic Healthy Volunteers (n:55) | $P$ value | OR (95% CI) |
|-------------------------------|--------------------------------------|--------------------------------------------------|-----------|-------------|
| **Genotypes**                 |                                      |                                                  |           |             |
| GG                            | 7                                    | 39                                               |           |             |
| GT                            | 13                                   | 15                                               |           |             |
| TT                            | 1                                    | 1                                                |           |             |
| **Alleles**                   |                                      |                                                  |           |             |
| G allele                      | 27/0.643                             | 93/0.846                                         |           |             |
| T allele                      | 15/0.357*                            | 17/0.154                                         |           |             |

*Significant; OR: odds ratio; SNP: single-nucleotide polymorphism.

Table 3. The comparison of genotypes and allele frequency of target $eNOS$ Glu298Asp SNP for the current hypertensive and normotensive psoriatic sub-group patients.

| $eNOS$ Glu298Asp Polymorphism | Hypertensive Psoriatic Group (n:21) | Normotensive Non-Psoriatic Group (n:54) | $P$ value | OR (95% CI) |
|-------------------------------|--------------------------------------|-----------------------------------------|-----------|-------------|
| **Genotypes**                 |                                      |                                          |           |             |
| GG                            | 7                                    | 31                                      |           |             |
| GT                            | 13                                   | 19                                      |           |             |
| TT                            | 1                                    | 4                                       |           |             |
| **Alleles**                   |                                      |                                          |           |             |
| G allele                      | 27/0.643                             | 93/0.846                               |           |             |
| T allele                      | 15/0.357                             | 27/0.250                               |           |             |

OR: Odds ratio; SNP: single-nucleotide polymorphism

Human $eNOS$ gene is frequently polymorphic, and many studies have been performed on the relationship between $eNOS$ gene region polymorphisms and coronary artery diseases and hypertension. In their study performed on 226 primary hypertension patients and 200 healthy controls, Srivastava et al compared patients having GT+TT genotype with the control group to define $eNOS$ Glu298Asp mutation using the PCR-restriction fragment length polymorphism (RFLP) method. They found that the primary hypertension risk increased by 2.10 folds. Li et al showed that $eNOS$ Glu298Asp polymorphism was related to hypertension in females. Tian et al, Velloso et al, Periaswamy et al and Kim et al reported that $eNOS$ Glu298Asp poly-
morphism was related to hypertension. However, Wolff et al.\(^26\) and Kishimoto et al.\(^27\) reported that eNOS Glu298Asp polymorphism was not related to hypertension. Actually, the effects of eNOS were studied in Turkish patients with essential hypertension, and the results showed that polymorphism increases the risk of hypertension in the case of high serum total cholesterol levels.\(^31\)

This study is significant because it has been the first study that has investigated the correlation of eNOS Glu298Asp polymorphism and hypertension among psoriasis cases in the Turkish population. Also the study is more reliable because all the data were collected using the real-time PCR method. The previous studies performed in the Turkish population focused only on psoriasis or hypertension.\(^30,31\)

In a study conducted on psoriasis cases from the Turkish population in which eNOS gene polymorphism was investigated with the MboI RFLP method, it was detected that eNOS polymorphism was significant for psoriasis. Yet, the MboI RFLP method has a disadvantage due to the lack of enzyme recognition specify of the target sequences at the SNP. In our present study, real-time PCR method—a new, valid, and reliable method—was used in eNOS genotyping in patients and controls. The findings of the present study indicated that allele positivity at the 298 G/T region in eNOS gene increases the psoriasis risk 2.37 times (95% CI 1.14-4.96, \(P=.020\)) more in psoriatic patients than in normotensive and non-psoriatic volunteers and supports the previous study findings.\(^30\) Aside the differences in method, Senturk et al. did not analyze the association of Glu298Asp with eNOS gene in risk-related subgroups such as hypertensive psoriatic cases.\(^10\)

The results in the present study indicated that polymorphism in the eNOS Glu298Asp gene region was a significant and prominent risk factor for hypertension in psoriatic patients. When hypertensive psoriatic patients were compared with healthy individuals (normotensive, non-psoriatic individuals) and non-hypertensive psoriatic patients, the conversion of single G allele into T allele increased the hypertension risk 3.04 folds and 1.67 folds, respectively. The current preliminary results were consistent with the literature; nevertheless, the results need to be confirmed by large-scale studies.\(^22-25,30\)

eNOS gene polymorphism causes endothelial dysfunction, which gives birth to diseases such as hypertension, diabetes mellitus type 2, and hypercholesterolemia. All these diseases are components of metabolic syndrome. Therefore, in our opinion, endothelial dysfunction is the main cause of metabolic syndrome, and eNOS gene polymorphism is one of the most important reasons for its development. We think that an increased risk of hypertension in psoriatic patients is an important evidence for metabolic syndrome-psoriasis relation. According to this study, suggesting lifestyle modifications (diet, sport, weight loss, etc.), regular clinical examination, and avoiding drugs with cardiac side effects (acitretin base, TNF alpha blocker etc.) in treating psoriasis may contribute positively to psoriatic patients with eNOS Glu298Asp polymorphism who are suffering hypertension and diabetes. Present results showed that the T allele frequency of eNOS Glu298Asp SNP was different in hypertensive psoriatic patients, and the difference was statistically significant when compared with normotensive psoriatic patients and healthy controls (\textit{Tables 1-3}).

In conclusion, the results indicated that the Glu298Asp polymorphism of the eNOS gene appears to be an independent risk factor for psoriasis. It should also be considered that eNOS Glu298Asp polymorphism in psoriatic patients may provide a genetic susceptibility for hypertension. However, further investigations are necessary for confirming the association of eNOS Glu298Asp polymorphism with psoriasis and its relation with increase in the risk of hypertension among psoriatic patients.

\textbf{Acknowledgments}

The current research project was funded by the Scientific Research Center of Canakkale Onsekiz Mart University (BAP-2011/181).
NITRIC OXIDE SYNTHASE

REFERENCES

1. Gelfand JM, Mehta NM, Langan SM. Psoriasis and cardiovascular risk: strength in numbers. J Invest Dermatol. 2010;130(4):919-922
2. Prodanovic S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG. Association of psoriasis with coronary artery, cerebrovascular and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700-703
3. Ghazizadeh R, Shima H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci. 2010;7(15):284-289
4. Diessen RJ, Boezaart JB, Van de Kerkhof PC, De Jong EM. Cardiovascular risk factors in high need psoriasis patients and its implications for biological therapies. J Dermatol Treat. 2009;20(1):42-44
5. Friedewald VE, Carter JC, Gelfand JM, Gordon KB, Gibbons GH, Grundy SM, et al. AJC Editor’s Consensus: Psoriasis and coronary artery disease. Am J Cardiol. 2008;102(12):1631-1643
6. Gelfand JM, Neiman AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829-835
7. Gabriel SE. Heart disease in psoriasis J Am Acad Dermatol. 2006;55(5):829-835
8. Hemost. 2009;35(3):313-324
9. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost. 2008;34(3):313-324
10. Neiman AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(9):829-835
11. Maradit-Kremers H, McEvoy MT, Dann FJ, Champion HC, Bivalacqua TJ, D’Souza FM, Ortiz LA, Jeter JR, Toyoda K, et al. Gene transfer of endothelial nitric oxide synthase at -786 C/G polymorphism in a multi-ethnic population sample. J Hypertens. 2005;23(7):1361-1366
12. Takauka M. NOS gene polymorphism. Nihon Rinsho. 2004;62(1):103-109
13. Casas JP, Cavallari GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review Am J Epidemiol. 2006;164(10):921-935
14. Tangirik B, Özer N, Sayar N, Terzi S, Yaka Yılmaz H, Asiltürk R, et al. Endotelyal nitrik oksit sentezeti (eNOS) gen polimorfizminin (T-786 C) koroner arter hastalığını ile ilişkisi. Arch Turk Soc Cardiol. 2005;33:467-472. Turkish
15. Gerritsen ME. Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to human disease. Microcirculation 2005;12(1):129-140
16. Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab. 2000;70(4):241-251
17. Huang PI, Huang Z, Mashimo H, Bloch KD, Moskovitz MA, Bewan JA et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377 (6546):239-242
18. Lake-Bruse KD, Faraci FM, Shesely EG, Maeda N, Sigmund CD, Heistad DD. Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice. Am J Physiol. 1996;277(2):H-770-776
19. Zhang F, Wu S, Lu X, Wang M, Liu M. Gene transfer of endothelial nitric oxide synthase attenuates flow-induced pulmonary hypertension in rabbits. Ann Thorac Surg. 2008;85(2):581-585
20. Champion HC, Bivalacqua TJ, D’Souza FM, Ortiz LA, Jeter JR, Toyoda K, et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res. 1999;84:1422-1432
21. Salimi S, Fireozrai M, Zand H, Nakhaei A, Shafiee SM, Taviani H, et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism in patients with coronary artery disease. Ann Saudi Med. 2008;28(2):23-25. Turkish
22. Gilekon A, Adılen E. Psoriasis ve komorbiditeler. Turk Derm 2008;42(2):23-25. Turkish
23. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329(27):2002-2012
24. Takaoka M. NOS gene polymorphism. Nihon Rinsho.2004;62(11):103-109
25. Casas JP, Cavallari GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review Am J Epidemiol. 2006;164(10):921-935
26. Tangirik B, Özer N, Sayar N, Terzi S, Yaka Yılmaz H, Asiltürk R, et al. Endotelyal nitrik oksit sentezeti (eNOS) gen polimorfizminin (T-786 C) koroner arter hastalığını ile ilişkisi. Arch Turk Soc Cardiol. 2005;33:467-472. Turkish
27. Gerritsen ME. Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to human disease. Microcirculation 2005;12(1):129-140
28. Wang XL, Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease. Mol Genet Metab. 2000;70(4):241-251
29. Lake-Bruse KD, Faraci FM, Shesely EG, Maeda N, Sigmund CD, Heistad DD. Gene transfer of endothelial nitric oxide synthase (eNOS) in eNOS-deficient mice. Am J Physiol. 1996;277(2):H-770-776
30. Zhang F, Wu S, Lu X, Wang M, Liu M. Gene transfer of endothelial nitric oxide synthase attenuates flow-induced pulmonary hypertension in rabbits. Ann Thorac Surg. 2008;85(2):581-585
31. Champion HC, Bivalacqua TJ, D’Souza FM, Ortiz LA, Jeter JR, Toyoda K, et al. Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ Res. 1999;84:1422-1432
32. Salimi S, Fireozrai M, Zand H, Nakhaei A, Shafiee SM, Taviani H, et al. Endothelial nitric oxide synthase gene Glu298Asp polymorphism in patients with coronary artery disease. Ann Saudi Med. 2008;28(2):23-25. Turkish
33. Tian GX, Zeng XT, Wang XB, Zhang L, Zhang W, Wei WL. Association between the endothelial nitric oxide synthase gene Glu298Asp polymorphism and coronary heart disease: A metaanalysis of 39 case control studies. Mol Med Rep. 2013;7(4):1310-1318
34. Velloso MW, Pereira SB, Gouveia L, Chermont S, Tardín OM, Gonçalves R, et al. Endothelial nitric oxide synthase Glu298Asp gene polymorphism in a multi-ethnic population with heart failure and controls. Nitric Oxide. 2010;22(3):220-225
35. Periassamy R, Gurusamy U, Shewade DG, Cherian A, Swaminathan RP, Dutta TK, et al. Gender specific association of endothelial nitric oxide synthase gene (Glu298Asp) polymorphism with essential hypertension in a south Indian population. Clin Chim Acta. 2008;395(1-2):134-136
36. Kim JS, Cho JR, Park S, Shim J, Kim JB, Cho DK et al. Endothelial nitric oxide synthase Glu298Asp gene polymorphism is associated with hypertensive response to exercise in well-controlled hypertensive patients. Yonsei Med J. 2007;48(3):389-395
37. Wolff B, Grabe HJ, Schlüter C, Popowski K, Völzke H, Liddemann J, et al. Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens. 2009;27(7):1361-1366
38. Kishimoto T, Misawa Y, Kaetu A, Nagai M, Ōsaki Y, Okamoto M, et al. eNOS Glu298Asp polymorphism and hypertension in a cohort study in Japanese. Prev Med. 2004;39(5):927-931
39. Srivastava K, Narang R, Sreenivas V, Das S, Das N. Association of eNOS Glu298Asp gene polymorphism with essential hypertension in Asian Indians. Clin Chim Acta. 2008;387(1-2):80-83
40. Li J, Cun Y, Tang WR, Wang Y, Li SN, Ouyang HR et al. Association of eNOS gene polymorphisms with essential hypertension in the Han population in southwestern China. Genet Mol Res. 2011;10(3):2202-2212
41. Senturk N, Kara N, Aydin F, Gunes S, Yuksel EP, Canturk T, et al. Association of eNOS gene polymorphism (Glu298Asp) with psoriasis. J Dermatol Sci. 2008;48(1):52-55
42. Kayhan FE, Koldemir M, Cagatay P, Ciftci C, Susleyci-Duman B. Prevalence of endothelial nitric oxide synthase E298D polymorphism in Turkish patients with essential hypertension. Diabetes Metab Syndr. 2012;7(1):12-6.